Cullinan Therapeutics Inc News - CGEM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Annual Report (10-k)

0001789972--12-31http://fasb.org/us-gaap/2021-01-31#LicenseMemberFYhttp://fasb.org/us-gaap/2021-01-31#LicenseM...

Current Report Filing (8-k)

false 0001789972 0001789972 2022-03-17 2022-03-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter...

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a...

Securities Registration: Employee Benefit Plan (s-8)

As filed with the Securities and Exchange Commission on March 10, 2022 Registration No. 333-_____ ...

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a...

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual...

Current Report Filing (8-k)

false 0001789972 0001789972 2022-02-28 2022-02-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a...

CGEM new 52 week high

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CGEM News

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Annual Report (10-k)

Current Report Filing (8-k)

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

Securities Registration: Employee Benefit Plan (s-8)

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

Current Report Filing (8-k)

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

CGEM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM) News

Cullinan Therapeutics Inc (CGEM)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CGEM News

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Annual Report (10-k)

Current Report Filing (8-k)

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

Securities Registration: Employee Benefit Plan (s-8)

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

Current Report Filing (8-k)

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

CGEM Discussion

Your Recent History